Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Douglas Adam Rubinson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5337-5231; OpenAlex author ID A5044352034. Sources: OpenAlex.

Their work

Papers
37 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
148
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: 2 papers · 2016: 2 papers · 2017: 2 papers · 2018: 5 papers · 2019: 2 papers · 2020: 2 papers · 2021: 4 papers · 2022: 2 papers · 2023: 6 papers · 2024: 2 papers · 2025: 1 paper · 2026: 4 papers

Papers 37

  1. Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2026.04.005↗
  2. CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. Co-author DOI 10.1016/j.cell.2026.08.045↗
  3. Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial. Co-author DOI 10.1038/s43018-026-01165-8↗
  4. A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. Co-author DOI 10.1158/1078-0432.ccr-24-3766↗
  5. Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreat… Co-author DOI 10.1200/po-25-00332↗
  6. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-331074↗
  7. Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the T… Co-author DOI 10.1158/2326-6066.cir-23-1073↗
  8. USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. Co-author DOI 10.1016/j.xcrm.2023.101007↗
  9. Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyad002↗
  10. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Co-author DOI 10.1158/0008-5472.can-22-3050↗
  11. Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-3930↗
  12. A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancr… Co-author DOI 10.1158/1078-0432.ccr-23-2005↗
  13. Pancreatic Adenocarcinoma: Real World Evidence of Care Delivery in AccessHope Data. Co-author DOI 10.3390/jpm13091377↗
  14. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1125↗
  15. Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers14246223↗
  16. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Co-author DOI 10.1016/j.cell.2021.11.017↗
  17. Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3141↗
  18. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Co-author DOI 10.1158/2159-8290.cd-20-0841↗
  19. Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment o… Co-author DOI 10.21037/jgo-21-197↗
  20. Diabetes, Weight Change, and Pancreatic Cancer Risk. Co-author DOI 10.1001/jamaoncol.2020.2948↗
  21. Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-19-1315↗
  22. Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk. Co-author DOI 10.1038/s41416-019-0426-5↗
  23. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Co-author DOI 10.1038/s41436-018-0009-5↗
  24. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. First author DOI 10.1001/jamaoncol.2017.3420↗
  25. Statin use and pancreatic cancer risk in two prospective cohort studies. Co-author DOI 10.1007/s00535-018-1430-x↗
  26. Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2018.02.022↗
  27. Plasma inflammatory cytokines and survival of pancreatic cancer patients. Co-author DOI 10.1038/s41424-018-0008-5↗
  28. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Co-author DOI 10.1158/2159-8290.cd-18-0275↗
  29. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. First author DOI 10.1038/bjc.2017.349↗
  30. Cigarette Smoking and Pancreatic Cancer Survival. Co-author DOI 10.1200/jco.2016.71.2026↗
  31. Circulating Metabolites and Survival Among Patients With Pancreatic Cancer. Co-author DOI 10.1093/jnci/djv409↗
  32. Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. Co-author DOI 10.1200/jco.2015.66.3005↗
  33. Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.hoc.2015.04.012↗
  34. Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus. First author DOI 10.1200/jco.2014.57.5688↗
  35. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Co-author DOI 10.1038/nm.3686↗
  36. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. First author DOI 10.1634/theoncologist.2014-0086↗
  37. Prediagnostic body mass index and pancreatic cancer survival. Co-author DOI 10.1200/jco.2013.51.7532↗

Closest collaborators

The 25 strongest of 148 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brian Matthew Wolpin · 35 shared papers, 2013–2026 · strength 3.41
  2. Jonathan Andrew Nowak · 21 shared papers, 2017–2026 · strength 2.31
  3. Andrew J. Aguirre · 19 shared papers, 2018–2026 · strength 2.29
  4. Kimberly J. Perez · 17 shared papers, 2019–2026 · strength 2.19
  5. James M. Cleary · 16 shared papers, 2014–2026 · strength 2.15
  6. Kimmie Ng · 22 shared papers, 2013–2026 · strength 1.88
  7. Harshabad Singh · 12 shared papers, 2021–2026 · strength 1.77
  8. Chen Yuan · 21 shared papers, 2013–2024 · strength 1.50
  9. Thomas E. Clancy · 14 shared papers, 2015–2026 · strength 1.39
  10. Srivatsan Raghavan · 9 shared papers, 2021–2026 · strength 1.23
  11. Brandon M. Huffman · 7 shared papers, 2022–2026 · strength 1.12
  12. Vicente Morales‐Oyarvide · 14 shared papers, 2016–2023 · strength 1.01
  13. Matthew B.B. Yurgelun · 8 shared papers, 2019–2026 · strength 0.98
  14. Charles S. Fuchs · 16 shared papers, 2014–2021 · strength 0.94
  15. Andressa Dias Costa · 8 shared papers, 2020–2026 · strength 0.87
  16. Ana Babić · 11 shared papers, 2016–2024 · strength 0.77
  17. Joseph Douglas Mancias · 5 shared papers, 2022–2026 · strength 0.75
  18. Rishi Surana · 5 shared papers, 2022–2026 · strength 0.73
  19. Thomas Adam Abrams · 5 shared papers, 2023–2026 · strength 0.72
  20. Geoffrey Ira Shapiro · 5 shared papers, 2021–2026 · strength 0.64
  21. Andrea J. Bullock · 6 shared papers, 2017–2026 · strength 0.63
  22. Stephanie K. Dougan · 4 shared papers, 2022–2026 · strength 0.62
  23. Leah H. Biller · 4 shared papers, 2023–2026 · strength 0.60
  24. Edward L. Giovannucci · 10 shared papers, 2013–2020 · strength 0.55
  25. Peter Kraft · 10 shared papers, 2013–2020 · strength 0.55

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.